Essex Bio-Technology Adjusts Share Capital Following HKD 2,060 Buyback of 1,000 Shares

Bulletin Express10-13

Essex Bio-Technology Limited reported a marginal change in its share capital after repurchasing 1,000 ordinary shares on 13 October 2026. The shares were acquired on The Stock Exchange of Hong Kong at a single price of HKD 2.06 per share, resulting in a total outlay of HKD 2,060.

Following the transaction: • Issued shares (excluding treasury shares) decreased to 564.79 million. • Treasury shares increased to 2.22 million. • The bought-back shares represented 0.00018 % of the company’s issued share capital immediately before the transaction. • Total issued shares (including treasury shares) remain at 567.01 million.

Repurchases to date under the general mandate granted on 26 May 2026 now stand at 2.22 million shares, equivalent to 0.39 % of the shares outstanding on the mandate’s grant date. The mandate allows for the repurchase of up to 56.70 million shares.

In accordance with Hong Kong Listing Rules, Essex Bio-Technology is subject to a moratorium on issuing new shares or disposing of treasury shares until 12 November 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment